DJIA 16,735.38 -69.33 -0.41%
NASDAQ 4,390.40 -31.69 -0.72%
S&P 500 1,933.30 -12.86 -0.66%
market minute promo


3.65 -0.10 (-2.67%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $3.65 -2.67%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.74
Previous Close $3.75
Daily Range $3.66 - $3.83
52-Week Range $3.32 - $11.64
Market Cap $377.6M
P/E Ratio -3.61
Dividend (Yield) $0.00 (0.0%)
Volume 715,324
Average Daily Volume 2,855,411
Current FY EPS -$1.06





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

3 Biotechs Investors Should Watch

The healthcare version of Where the Money Is.

Premature Combination Use Of Belviq And Phentermine Is A Risk

Belviq Sales Benefit From Advertising - Up 2.8%

VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog

VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape

Vivus Up On Erectile Dysfunction Drug - What Should Investors Expect?

Today's Perilous Reversal Stock: Vivus (VVUS)

NASDAQ Biotech Top Performers (Pre-Open September 19)

Why VIVUS, Inc. Is Today's Best Biotech Stock

VIVUS stock is among today's top gainers after announcing the supplemental new drug approval for erectile dysfunction drug Stendra. Find out how this could impact VIVUS and its shareholders moving forward.

Why VIVUS (VVUS) Stock Is Up Today

See More VVUS News...

VVUS's Top Competitors

VVUS $3.65 (-2.67%)
Current stock: VVUS
JNJ $103.70 (-0.58%)
Current stock: JNJ
NVS $92.82 (-0.43%)
Current stock: NVS
RHHBY $36.33 (-1.13%)
Current stock: RHHBY